ABSTRAT OBJECTIVE: To probe into the treatment regimen of coronary heart disease patients with mild elevation of hepatic transaminases induced by statins. METHODS: Totally 93 cases of coronary heart disease patients with mild elevation of hepatic transaminases met the inclusion and exclusion criteria and admitted from Oct. to Dec. 2018 were extracted to be divided into 33 cases in the group A（withdrawal of statins）

33 cases in the group B（ without adjustment of lipid-regulating therapy group） and 27 cases in the group C[with adjustment of lipid-regulating therapy（categories or doses） ]according to patients’ prescription of statins after asymptomatic solitary mild elevation of hepatic transaminases. The general data

application of drugs

daily dose of statins and low density lipoprotein cholesterin（LDL-C） level of three groups were recorded. RESULTS: The hepatic transaminases levels of 93 patients returned to the normal range within 3 months after elevation. The largest proportion of prescriptions of statins before elevation in hepatic transaminases were pivastatin

atorvastatin and rosuvastatin. The largest proportion of prescriptions of statins afer elevation of hepatic transaminaseswere pitvastatin

pravastatin and atorvastatin. The proportion of prescriptions for pravastatin increased by 13. 87%. The compliance rates of LDL-C in group A

B and C were respectively 21. 21%（7/33）

60. 61%（20/33） and 37. 04%（10/27）

with statistically significant differences（P<0. 05）. The compliance rate of LDL-C in group A was significantly lower than that in group B（P < 0. 017）. The difference of compliance rate of LDL-C in group A and C was not statistically significant（P > 0. 017）

and the difference in groups B and C was not statistically significant（P>0. 017）. According to the telephone interview

61. 90%（13/21） of patients in group A took medicine according to prescription

78. 26%（18/23） of patients in group B took medicine according to prescription

and 52. 94%（9/17） of patients in group C took medicine according to prescription. No patients actually continued to take high-intensity statins. CONCLUSIONS: After administration of stains

patients with coronary heart disease can have asymptomatic solitary mild elevations of hepatic transaminases. In clinic

there are cases of withdrawal of statins or adjustment of statins

which affect the medication compliance of patients and the compliance rate of LDL-C.